Navigation Links
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Date:12/8/2008

to treatment or returns within six months of completing such treatment

Bulky tumors - when individual tumor masses are >5cm in diameter

Salvage therapy - a final treatment for people who are non-responsive to or cannot tolerate other available therapies for a particular condition and whose prognosis is often poor

Arzerra(TM) is the proposed registered trademark to be used in the United States and Europe.

To access the latest GSK Oncology media materials, visit www.gskcancermedia.com

    GSK Enquiries:
    Onsite Media
    enquiries:             Greg Clarke - non US media only   +1 610 405 0053
                           Ken Inchausti - US media only     +1 267 809 7552

    UK Media enquiries:    Philip Thomson                   +44 20 8047 5502
                           Claire Brough                    +44 20 8047 5502
                           Alice Hunt                       +44 20 8047 5502
                           Gwenan White                     +44 20 8047 5502

    US Media enquiries:    Nancy Pekarek                     +1 215 751 7709
                           Mary Anne Rhyne                   +1 919 483 2839
                           Sarah Alspach                     +1 215 751 7709

    European Analyst
    /Investor enquiries:   David Mawdsley                   +44 20 8047 5564
                           Sally Ferguson                   +44 20 8047 5543
                           Gary Davies                      +44 20 8047 5503
    US Analyst/ Investor
     enquiries:            Jen Hill                          +1 215 751 7002
                           Tom Curry                         +1 215 751 5419

    Genmab enquiries:      Helle Husted, Sr. Director, Investor Relations
                           T: +45 33 44 77 30;
                           M: +45 25 27 47
'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
(Date:7/24/2014)... July 24, 2014  Restore Health, a leading ... pharmaceuticals, announced that it is now offering pharmacogenetics ... each individual based upon their particular genetic makeup. ... the interaction between a patient,s genetics and their ... excited to provide this new service to healthcare ...
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
... 3 Reportlinker.com announces that a new ... catalogue. , Wheelchair Market Shares, ... , http://www.reportlinker.com/p0157387/Wheelchair-Market-Shares-Strategies-and-Forecasts-Worldwide-2009-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... This 2009 study has 484 pages, 235 ...
Cached Medicine Technology:Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 2Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 3Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 4Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 5Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 6Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 7Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 8Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 9Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 10Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 11Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 12Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 13Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 14Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 15Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 16Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 17Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 18Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 19Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 20Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 21
(Date:7/27/2014)... University scientists have shown that a powerful drug given ... only halves the early risk of rejection, but that ... drugs to be used after the operation. , The ... and presented at the World Transplant Congress in San ... difficult transplant conundrum: the powerful combinations of treatments used ...
(Date:7/27/2014)... July 27, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. , Endoscopy procedures are performed ...
(Date:7/27/2014)... constant expansion of companies across the globe has led ... factors that have increased this demand include the application ... learning and development, security and safety, and knowledge sharing ... video market value has crossed $11.21 billion in 2013 ... with a compound annual growth rate (CAGR) of 25.97%. ...
(Date:7/27/2014)... July 27, 2014 The North American ... estimated at $1570 million in 2014, and it is ... CAGR of 4.64%. The report incorporates the factors that ... expectations of growth rates and projected total expenditure. The ... the global markets. Apart from the general overview of ...
(Date:7/27/2014)... (Sunday July 27 11:45 am ET): A ... the surgical sitehas been reduced by 77 percent ... the American College of Surgeons National Surgical Quality ... case study presented at the 2014 ACS NSQIP ... Columbia, reportedly reduced its rate of cardiac surgical ...
Breaking Medicine News(10 mins):Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4
... , PALO ALTO, Calif., Aug. 10 ... will report its second quarter 2009 financial results on Tuesday, August 11, ... to discuss the results, provide guidance for 2009, and give a company ... Time. , , The live webcast and press release ...
... Aug. 10 VION PHARMACEUTICALS, INC. (OTC Bulletin ... Oncologic Drugs Advisory Committee (ODAC) Meeting at which its lead ... , , The ODAC reviews and evaluates ... human drug products for use in the treatment of cancer ...
... 10, 2009 UT Southwestern Medical Center researchers are ... track down and kill cancer cells in patients with ... Researchers are testing a tumor-specific protein called recombinant ... interact with the body,s immune system and generate a ...
... - Researchers from Indiana University,s Center for Health Policy ... government-sponsored health insurance for individuals under age 65 remains ... described or how involved the government would be. ... a government-sponsored health insurance option, such as that being ...
... help contribute to obesity among its users, according to a ... Researchers found that the average user of food stamps had ... The link between food stamps and higher weight was almost ... BMI than those not in the program, the study found. ...
... of all human cancer tumors, the Ras protein literally "drives ... Faculty of Life Sciences at Tel Aviv University. Prof. Kloog ... anti-Ras drug against pancreatic cancer, currently in clinical trials. Now, ... Journal of Pharmacology shows that the drug might be able ...
Cached Medicine News:Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 2Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 3Health News:UT Southwestern researchers launch study into search-and-destroy antigen for deadly skin cancer 2Health News:Americans remain divided on government involvement in health insurance, IU survey shows 2Health News:Americans remain divided on government involvement in health insurance, IU survey shows 3Health News:Food stamp use linked to weight gain, study finds 2Health News:Food stamp use linked to weight gain, study finds 3Health News:Taking the needle's sting out of diabetes 2
Inquire...
Inquire...
Inquire...
Inquire...
Medicine Products: